Journal article
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
Abstract
BACKGROUND: In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk. Whether these benefits are dose related remains uncertain.
METHODS: Participants were randomly assigned in a …
Authors
Gerstein HC; Li Z; Ramasundarahettige C; Baek S; Branch KRH; Del Prato S; Lam CSP; Lopes RD; Pratley R; Rosenstock J
Journal
Circulation, Vol. 147, No. 13, pp. 1004–1013
Publisher
Wolters Kluwer
Publication Date
March 28, 2023
DOI
10.1161/circulationaha.122.063716
ISSN
0009-7322